Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Active, not recruitingPhase 2 以催乳颗粒为对照,评价乳欣片治疗产后缺乳气血虚弱证有效性和安全性随机双盲双模拟平行对照多中心临床研究
[Translation] A randomized double-blind, double-dummy, parallel controlled, multicenter clinical study to evaluate the efficacy and safety of Ruxin Tablets in the treatment of postpartum deficiency of milk and qi and blood deficiency, using Cuiru Granules as a control.
1.初步评价乳欣片治疗产后缺乳(气血虚弱证)的有效性;
2.初步评价乳欣片治疗产后缺乳(气血虚弱证)的安全性;
3.探索乳欣片与催乳颗粒比较治疗产后缺乳(气血虚弱证)的临床应用优势。
[Translation] 1. To preliminarily evaluate the effectiveness of Ruxin Tablets in treating postpartum lactation (Qi and blood deficiency syndrome);
2. To preliminarily evaluate the safety of Ruxin Tablets in treating postpartum lactation (Qi and blood deficiency syndrome);
3. To explore the clinical application advantages of Ruxin Tablets compared with Cuiru Granules in treating postpartum lactation (Qi and blood deficiency syndrome).
100 Clinical Results associated with Qingdao Huanuo Pharmaceutical Biotechnology Co., Ltd.
0 Patents (Medical) associated with Qingdao Huanuo Pharmaceutical Biotechnology Co., Ltd.
100 Deals associated with Qingdao Huanuo Pharmaceutical Biotechnology Co., Ltd.
100 Translational Medicine associated with Qingdao Huanuo Pharmaceutical Biotechnology Co., Ltd.